iStent Infinite and iDose TR for Management of Moderate to Severe Primary Open Angle Glaucoma Are a Safe and Effective Alternative to Filtering Surgery for IOP Reduction in Patients With Medically Uncontrolled Glaucoma. (POAG)

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

开始日期2026-01-05

申办/合作机构

Wills Eye Institute

[+1]

NCT07400926

/ RecruitingN/A

Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg

Clinical in-use observational trial to evaluate the updated inserter for the Travoprost Intracameral implant using the updated inserter (Model G2-TRIO)

开始日期2025-12-17

申办/合作机构

Glaukos Corp.

100 项与曲伏前列素相关的临床结果

登录后查看更多信息

100 项与曲伏前列素相关的转化医学

登录后查看更多信息

100 项与曲伏前列素相关的专利（医药）

登录后查看更多信息

763

项与曲伏前列素相关的文献（医药）

2026-02-01·DRUGS & AGING

Implants to Treat Glaucoma: Promising or Not?

Review

作者: Kolko, Miriam ; Cvenkel, Barbara

Glaucoma is one of the leading causes of blindness and its prevalence increases with age. The most common form, primary open-angle glaucoma, is a chronic, slowly progressive optic neuropathy characterised by the loss of retinal ganglion cells and their axons, leading to irreversible visual field loss. Elevated intraocular pressure (IOP) is the only modifiable risk factor for glaucoma. Reducing IOP to a level that is safe for the patient's eye has been shown to slow disease progression. Lowering IOP in open-angle glaucoma is achieved by eye drops, selective laser trabeculoplasty (SLT) and/or surgery. Many patients are treated with IOP-lowering eye drops, which require lifelong continuous instillation. However, as with other chronic, asymptomatic diseases, adherence to glaucoma treatment is poor for various reasons and is associated with faster disease progression. The purpose of this review is to discuss several sustained-release systems that have been investigated to reduce IOP over time, to address barriers to adherence and improve quality of life. Among these, non-invasive drug-eluting delivery systems such as contact lenses, punctal plugs, and conjunctival ocular inserts have not reached the market. Currently, only two intracameral implants have been approved by the Food and Drug Administration for single use due to corneal safety issues. The biodegradable bimatoprost implant releases the drug continuously for 4-6 months, and its effect on IOP may extend for up to 2 years in 25% of patients. The non-biodegradable intracameral implant releases travoprost for 36 months, when it needs to be removed. However, additional data are needed to assess safety following repeated administration, as well as in broader patient populations and in combination with other treatment approaches such as SLT. Several other biodegradable intracameral implants that release prostaglandin analogues are undergoing clinical trials. In the future, intraocular implants containing genetically modified cells that secrete neurotrophic factors may potentially offer an IOP-independent neuroprotective strategy, complementing existing IOP-lowering implants in glaucoma management.

2026-01-01·ARQUIVOS BRASILEIROS DE OFTALMOLOGIA

Beyond pressure control: Periorbital impact of prostaglandins vs. laser trabeculoplasty.

Article

作者: Lavinsky, Daniel ; Pakter, Marina M ; Leivas, Leonardo ; Almeida, Rafaela C ; Fabris, Marcelo V ; Lindenmayer, Rodrigo L ; Pakter, Helena M ; Lavinsky, Fábio ; Procianoy, Fernando

PURPOSE:

To assess the one-year impact of prostaglandin analog (travoprost) on periorbital appearance and lower eyelid horizontal tension, compared with the contralateral eye treated with Pascal selective laser trabeculoplasty.

METHODS:

This nested case-control study was derived from a non-inferiority randomized clinical trial comparing Pascal selective laser trabeculoplasty efficacy with travoprost in fellow eyes over 12 months. One eye received daily travoprost, while the contralateral eye underwent Pascal selective laser trabeculoplasty. Lower eyelid horizontal tension was measured using a validated digital imaging method, and prostaglandin-associated periorbitopathy signs were graded by masked observers. Statistical analyses included generalized estimating equations and the Mann-Whitney U test for nonparametric data, with p<0.05 considered significant.

RESULTS:

Ten patients met the inclusion criteria for this subanalysis. Travoprost-treated eyes had significantly lower mean lower eyelid distension compared with Pascal selective laser trabeculoplasty-treated eyes (4.32 mm vs. 5.02 mm; mean difference: 0.70 mm; p<0.001). Prostaglandin--associated periorbitopathy scores were significantly higher in the travoprost group, reflecting more pronounced changes in ptosis, periorbital hyperpigmentation, and eyelid retraction.

CONCLUSIONS:

Chronic use of prostaglandin analogs is associated with notable periorbital changes and increased lower eyelid tension, potentially affecting aesthetics and ocular function. Pascal selective laser trabeculoplasty may offer a safer profile for preserving periorbital anatomy while maintaining effective intraocular pressure control. Laser trabeculoplasty should be considered as an initial treatment when appropriate to minimize cosmetic and functional changes from chronic topical therapy.

2025-12-01·Ophthalmology and Therapy

Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting

Article

作者: Kothe, Angela C ; Navratil, Tomas ; Applegate, David ; Singh, Inder Paul ; Reiss, George R ; Usner, Dale W ; Flowers, Brian E ; Katz, L Jay

INTRODUCTION:

The purpose of this analysis was to assess the safety outcomes of a subgroup of patients who received a travoprost intracameral implant in an office-based surgery setting from one of the phase 3 registration trials, GC-012, for the implant.

METHODS:

Adult patients with open-angle glaucoma or ocular hypertension on 0 to 3 pre-study intraocular pressure (IOP)-lowering medications underwent a washout period (if applicable). Patients who qualified based on having an unmedicated mean diurnal IOP of 21 mmHg or greater and an IOP of 36 mmHg or less at each of the diurnal timepoints received a travoprost intracameral implant and were followed for safety outcomes at eight visits over a 12-month period. Safety evaluations included adverse events, slit-lamp examination, gonioscopy, pachymetry, dilated fundus examination, specular microscopy, perimetry, and best-corrected visual acuity.

RESULTS:

A total of 37 patients received a travoprost intracameral implant in an office-based surgery setting. Administration of the implant was successful in 100% of patients. There were no serious ocular adverse events or ocular infections in patients administered the implant.

CONCLUSIONS:

This subgroup analysis demonstrated that administration of the travoprost intracameral implant in an office-based surgery setting was safe and well tolerated.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT03868124.

185

项与曲伏前列素相关的新闻（医药）

2026-04-01

·GlobeNewswire-Health Care

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in April 2026. Ocular plans to present additional data and analyses from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD). Upcoming Scientific Conferences: 14th Annual Vit-Buckle Society (VBS) Meeting: April 9 - 11, 2026Las Vegas, Nevada Symposium Title: Redefining the Management of Neovascular AMDSymposium Date/Time: Saturday, April 11, 2026, 1:15 – 2:00 PM PDTPresenters: Jeffrey S. Heier, MD, Chief Scientific Officer at Ocular Therapeutix, Peter K. Kaiser, MD, Chief Development Officer at Ocular Therapeutix, and Andrew A. Moshfeghi, MD, MBA, FASRS, USC Roski Eye Institute A copy of the VBS symposium presentation will be made available on Ocular’s website following the presentation on Saturday, April 11, 2026. Congreso Nacional de Oftalmologia (CNO) 2026: April 15 - 17, 2026Buenos Aires, Argentina Presentation Title: What are TKIs and What Do They Do?Session: SARyV: Macular Diseases (SARyV: Enfermedades maculares)Session Date/Time: Wednesday, April 15, 2026, 10:35 – 10:50 AM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix Presentation Title: Current State of Treatment of Diabetic Retinal DiseaseSession: Current state of treatment of diabetic retinal diseaseSession Date/Time: Wednesday, April 15, 2026, 1:30 – 1:45 PM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix Presentation Title: Current State of Treatment of Neovascular AMDSession: Wet AMD: The Debate (DMAE Húmeda: el debate)Session Date/Time: Wednesday, April 15, 2026, 3:45 – 4:00 PM ART (UTC-3)Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO at Ocular Therapeutix Exact medical conference presentation times may be subject to change. About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program. Follow the Company on its website, LinkedIn, or X. DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc. Investors & MediaOcular Therapeutix, Inc.Bill SlatteryVice President, Investor Relationsbslattery@ocutx.com

临床3期临床2期

2026-03-27

·QQ浏览器

兆科眼科三大核心资产步入“收获期” 阿托品赛道竞争加剧

3月25日，兆科眼科（6622.HK）发布2025年全年业绩。年报显示，公司去年实现收入0.32亿元，其中药物及产品销售收入为0.31亿元。研发开支为1.71亿元，同比减少15.7%。兆科眼科发布2025年全年业绩。南都N视频记者注意到，兆科眼科旗下硫酸阿托品滴眼液、环孢素眼用凝胶、贝伐单抗注射液三大核心资产均已进入上市审评阶段，这也意味着兆科眼科多年研发投入即将迈入商业化兑现期。截至2025年底，公司持有现金及现金等价物0.96亿元。公司对此表示，财务状况稳健，有能力支持后续产品的商业化上市及创新药物的持续临床开发。三款核心资产同步冲刺上市从产品管线来看，兆科眼科多项资产在2025年取得实质性进展，其中三大核心产品均进入新药申请阶段。硫酸阿托品滴眼液（NVK002）的0.01%和0.02%两项浓度配方，目前均在中国接受监管机构的产品上市审评。国家药监局于2025年1月接受了0.01%浓度阿托品的简易新药申请，同年7月接受了0.02%浓度阿托品的新药申请。环孢素眼用凝胶方面，再次递交的新药申请于2025年5月获国家药监局受理。同年6月，该产品获得了美国食品药物管理局（FDA）的临床试验（IND）批准，允许在美国启动III期临床试验。贝伐单抗玻璃体注射液（TAB014）的生物制剂许可申请于2025年6月获国家药监局受理，这是中国首例提交BLA的针对湿性年龄相关性黄斑病变（wAMD）的贝伐单抗产品。除了中国市场外，公司正着力推进BRIMOCHOL™ PF在韩国的引进工作，以及硫酸阿托品滴眼液（0.01%）在澳大利亚的引进工作，这两款药物目前均在其各自市场接受新药申请的审评。兆科眼科董事会主席、执行董事兼行政总裁李小羿博士表示：“2025年，公司在三大核心资产上取得了重大监管突破，并通过与国际知名制药公司的合作，持续拓展了全球版图，迎来了公司历史上最成功的一年。”此外，青光眼是世界致盲眼病之一，兆科眼科对此已形成较为完善的产品组合。记者了解到，公司于2025年3月获得青光眼仿制药拉坦噻吗滴眼液的上市批准，完成了青光眼药物管线布局。目前，公司的青光眼产品组合涵盖贝美素噻吗洛尔滴眼液（晶贝莹®）、贝美前列素滴眼液（晶贝清®）、拉坦前列素滴眼液、拉坦噻吗滴眼液、曲伏前列素滴眼液及曲伏噻吗滴眼液。公司亦于2025年8月取得先进眼压测量设备TONO-i的监管注册批准，进一步完善了兆科的青光眼产品组合，使兆科眼科能更全面地服务国内青光眼患者，并协助医师提供更丰富的治疗药物选择。硫酸阿托品滴眼液赛道竞争激烈在三大核心资产中，硫酸阿托品滴眼液所处的近视防控赛道最受市场关注。中国近视人口基数庞大，儿童青少年近视率居全球前列，这一市场被寄予厚望。兆科眼科进入的是一个“竞争加速”的赛道。2024年3月，兴齐眼药的0.01%硫酸阿托品滴眼液率先获批上市，成为国内首款延缓儿童近视进展的产品。此后，兴齐眼药0.02%、0.04%硫酸阿托品滴眼液获批上市，共同构建近视防控梯度浓度产品矩阵。与此同时，恒瑞医药、欧康维视、齐鲁制药等企业的同类产品也在快速推进。这意味着，未来1-2年内，阿托品市场将进入多强并立的竞争格局。面对竞争，兆科眼科的硫酸阿托品滴眼液以差异化优势定位市场。公告显示，该硫酸阿托品滴眼液采用专利配方，成功解决低浓度阿托品的不稳定性，于美国及中国均获得专利保护，且不含防腐剂，预计保存期24个月以上。2025年7月，硫酸阿托品滴眼液（0.02%剂量）提交的新药申请已获得国家药监局的受理审查。2026年1月，硫酸阿托品滴眼液（0.01%剂量）注册申请已获得澳大利亚TGA受理，进行评核。兆科眼科的硫酸阿托品滴眼液以差异化优势定位市场。李小羿博士表示，展望2026年，兆科正进入转型的关键阶段，多项处于后期研发阶段的资产正逐步迈向商业化，全球市场影响力持续扩大。公司将聚焦加速监管审批、推进临床研究、强化商业化能力，目标于2026年将商业化药物种类增加至12款，借此带动收入增长，为患者及股东创造长期价值。采写：南都N视频记者伍月明

2026-03-18

·动脉网

【里程碑】眼压最大降幅10mmHg！青光眼双重机制新药中美NDA在即

近日，法国眼科生物技术公司Nicox SA（巴黎泛欧交易所代码：FR0013018124，ALCOX，下称Nicox）在美国青光眼学会年会（AGS 2026）上公布了其主要候选药物NCX 470的III期临床研究最新数据。结果显示，在关键性DENALI试验中，0.1%浓度的NCX 470在治疗开角型青光眼或高眼压症患者时表现出显著且持续的降眼压效果，与基线相比最大降幅达到10 mmHg，并在所有评估时间点达到对拉坦前列素（Latanoprost）的非劣效性终点。 01 从单通路到双通路的机制创新青光眼是一种以视神经损伤为核心特征的慢性眼病，而升高的眼内压（IOP）是目前唯一被证实可以通过治疗有效控制的危险因素。因此，几乎所有青光眼药物研发的核心目标都集中在一个方向：更有效地降低眼内压。当前临床一线药物主要是前列腺素类似物，例如拉坦前列素、比马前列素（Bimatoprost）、曲伏前列素（Travoprost）等，这些药物通过增加葡萄膜-巩膜通路（uveoscleral outflow）促进房水外流，从而降低眼内压。凭借每日一次给药、疗效稳定以及安全性成熟等优势，前列腺素类药物已经成为全球青光眼治疗的标准一线方案。然而，其降压能力通常在25%–30%左右。对于相当一部分患者而言，这一降压幅度仍不足以达到目标眼压，因此往往需要加用第二种甚至第三种药物。而多一种药物，就是给患者药物依从性上难度。 NCX 470的设计理念正是针对这一临床痛点。该药物本质上是比马前列素与一氧化氮供体（NO-donor）的结合分子。滴眼后，药物在眼部组织中代谢释放两种活性成分。一方面，比马前列素部分延续了传统前列腺素类药物的作用机制，促进葡萄膜-巩膜通路房水外流；另一方面，释放的一氧化氮则能够松弛小梁网和平滑肌结构，降低Schlemm管（施莱姆氏管）阻力，从而增强小梁网通路（trabecular outflow）。换句话说，NCX 470同时作用于两条主要房水外流通道，实现所谓的“双通路降压”。这一策略在理论上具有明显优势。传统前列腺素类药物主要作用于葡萄膜通路，而青光眼患者房水外流受阻的主要位置恰恰往往在小梁网。通过一氧化氮介导的小梁网松弛，NCX 470 有望在保证安全性的同时进一步增强降眼压效果。事实上，一氧化氮供体技术在眼科领域并非完全陌生。公司此前上市的另一款产品Vyzulta®便采用类似机制。但NCX 470在分子设计上选择了比马前列素作为前列腺素骨架，这一选择本身就具有潜在优势，因为比马前列素在临床实践中普遍被认为降压能力略强于拉坦前列素。因此，可以说NCX 470的核心目标明确：在保持前列腺素类药物良好耐受性的基础上，打造更强降眼压能力的单药治疗。 02 眼压最大降幅达到10 mmHg NCX 470的关键III期研究主要包括MONT BLANC与DENALI两项全球多中心临床试验。这些研究将NCX 470与标准剂量的比马前列素进行直接比较，以评估其降眼压能力。试验入组患者主要为原发性开角型青光眼或高眼压症患者，这也是目前降眼压药物最常见的治疗人群。美国受试者的基线人口统计学特征与眼部特征 DENALI是一项随机、双盲、多中心III期临床研究，旨在评估NCX 470在开角型青光眼（OAG）或高眼压症（OHT）患者中的疗效与安全性。该研究由美国杜克大学医学中心的Sanjay Asrani 博士在大会上进行报告。美国亚组III期denali试验的研究设计，主要疗效终点评估时间点为第2周、第6周及第3个月研究结果显示，0.1% NCX 470在所有主要评估时间点均达到相对于0.005%拉坦前列素的预设非劣效性标准。与此同时，在6个时间点中的3个时间点，NCX 470 实现了统计学意义上的更大眼压下降幅度。第2周、第6周及第3个月时，NCX 470与拉坦前列素在眼压降低方面的均值差异从整体疗效表现来看，NCX 470在研究期间展现出快速、强效且持续的降眼压作用，更重要的是，与基线相比最大降幅达到10 mmHg。这一降压幅度在目前单药治疗方案中具有较强竞争力。美国受试者中使用NCX 470 0.1%与使用拉坦前列素的平均眼压随时间变化在安全性方面，NCX 470整体耐受性与前列腺素类药物相似。最常见的不良反应包括结膜充血和轻度眼部刺激，但总体发生率处于可接受范围内。相比之下，一些新机制药物（例如Rho激酶抑制剂）往往会出现较高比例的结膜充血，从而影响患者依从性。从临床角度来看，这一点尤为重要。青光眼是一种需要长期甚至终身用药的慢性疾病，任何影响患者依从性的因素都会在真实世界中放大。因此，NCX 470的临床数据不仅展示了更强的降压能力，同时也维持了前列腺素类药物成熟的安全性特征。这种“疗效增强但安全性不显著恶化”的平衡，正是改良型眼科药物成功的重要因素。 03 中美NDA申报在即，FDA反馈总体积极除临床数据外，Nicox近期还披露了NCX 470的监管进展。2026年2月16日，公司宣布已与美国FDA完成新药申请（NDA）递交前会议。根据FDA提供的书面反馈，监管机构认为目前已有的临床数据以及公司计划提交的NDA内容和格式总体符合申报要求。FDA仅建议补充一项药代动力学（PK）数据，该数据将来自日本开展的一项小规模临床研究。 Nicox表示，该补充数据不会影响整体申报时间表，公司仍计划在2026年夏季向FDA提交 NCX 470的NDA。在商业合作方面，Nicox已将NCX 470的全球主要市场商业化权利授权给日本制药企业 Kowa Company。在中国及部分亚洲地区，该产品的权益则授权给了欧康维视，目前中国正在进行III期临床。根据协议，若产品成功上市，Nicox有望获得里程碑付款以及未来销售收入分成。青光眼是全球最主要的致盲性疾病之一。据流行病学研究估计，到2040年全球青光眼患者数量可能超过1亿人。庞大的患者基数，使得降眼压药物市场长期保持稳定规模。目前全球青光眼药物市场规模约为70–80亿美元。其中，前列腺素类药物仍占据最大的市场份额。与此同时，在这一市场中，大量核心药物已经专利到期，仿制药竞争激烈，价格普遍较低。因此，新药想要获得商业成功，往往需要在临床定位上形成明确差异，而不是单纯依靠“全新机制”。 NCX 470的潜在定位正是如此。它很可能不会取代传统PGA（前列腺素衍生物）作为首选初始治疗，而是成为传统前列腺素单药治疗后的升级方案。从长期来看，NCX 470的商业潜力主要取决于其在真实世界中的降压效果是否能够持续优于传统前列腺素类药物，此外，就是医生是否愿意将其作为“强化型单药”纳入治疗路径。如果这两点能够得到保证，NCX 470有望在青光眼药物市场中占据稳定份额。关于Nicox Nicox SA 是一家总部位于法国的跨国眼科公司，专注于利用其一氧化氮供体技术来开发眼科药物，提供维持视力和改善眼部健康的创新方案。该公司处于临床研发阶段，核心产品包括用于治疗青光眼的 NCX 470，并有已商业化的产品VYZULTA®和ZERVIATE®，后者已于2024年9月19日在中国获批上市。 VYZULTA®，0.024%，是一种一氧化氮供体前列腺素F2a类似物，适用于降低开角型青光眼或高眼压患者的眼压。该产品在全球范围内独家授权给全球领先的眼科健康公司Bausch + Lomb。VYZULTA®已在包括美国在内的超15个国家完成商业化，并且在其他多个国家获得批准。Nicox已于2024年10月将VYZULTA的版税收入出售给Soleus Capital。 ZERVIATE®，0.24%，适用于治疗过敏性结膜炎引起的眼痒，由公司的合作伙伴Harrow负责在美国的商业化。此外，在中国，则由欧康维视销售。公司已经将ZERVIATE独家授权给欧康维视，后者正负责产品在中国及大部分东南亚市场的开发和商业化。在研管线NCX 1728是一种处于临床前研究阶段的“一氧化氮供体型磷酸二酯酶-5 (PDE5) 抑制剂”类新药。和NCX 470一样，它具有双重作用机制：释放一氧化氮和抑制 PDE5，从而增强并延长降低眼压和神经保护的作用，有望治疗青光眼和视网膜疾病。如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。动脉网，未来医疗服务平台

临床3期临床2期临床结果

100 项与曲伏前列素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01964	曲伏前列素	S01EE04	DB00287

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
青光眼	日本	Novartis Pharmaceuticals Corp.	2007-07-31
开角型青光眼	美国	Alcon Pharmaceuticals Ltd.	2001-03-16
高眼压症	美国	Alcon Pharmaceuticals Ltd.	2001-03-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高血压	申请上市	美国	Glaukos Corp.	2023-05-05
青光眼相关色素分散综合征	临床3期	-	Alcon Research Ltd.	2011-11-01
闭角型青光眼	临床3期	美国	Alcon Research Ltd.	2000-01-01
闭角型青光眼	临床3期	澳大利亚	Alcon Research Ltd.	2000-01-01
虹膜色素剥脱综合征	临床阶段不明	美国	Alcon Research Ltd.	2003-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06582732 (Pubmed \| Ophthalmol Ther)	临床2期	开角型青光眼	210	Travoprost Intracameral Implant	選壓窪繭選淵衊餘範淵(簾餘鏇憲衊積醖醖製醖) = 鬱繭鑰衊願蓋蓋鬱鏇範憲製鹽膚簾簾憲獵艱選 (壓艱膚窪選窪窪憲餘襯 )	积极	2025-03-24
NCT06061718 (Pubmed \| Ther Adv Ophthalmol)	临床3期	眼科外科手术	60	Travoprost intracameral implant + Cataract surgery	艱窪鹹憲遞艱簾願觸蓋(鑰選壓觸鹽繭廠範窪襯) = Study eye adverse events were reported in 8.3% of patients 壓鏇製繭選繭選淵餘憲 (鹽製構選憲襯艱艱網蓋 ) 更多	积极	2025-01-01
NCT06582732 (CTgov)	临床2期	开角型青光眼	210	Travoprost Intracameral Implant exchanged at Month 12 (Cohort 1 (12-month Exchange))	繭齋簾鹹蓋願膚築願壓(齋願範積鹽遞網繭襯壓) = 廠鹹網壓窪簾襯艱遞鏇鑰顧築積窪範餘糧齋遞 (淵簾糧範範鏇窪蓋遞鏇, 3.02) 更多	-	2024-10-15
				Travoprost Intracameral Implant exchanged at Month 3 (Cohort 2 (3-month Exchange))	蓋繭鬱憲鏇鏇構選獵憲(繭觸鏇蓋顧網範遞壓獵) = 顧選鬱遞齋鹽醖淵醖範構選艱願簾膚簾壓襯選 (憲觸鬱積獵鏇鏇餘壓鑰, 2.50) 更多
NCT04360174 (CTgov)	临床1期	高眼压症 \| 开角型青光眼	19	OTX-TIC (OTX-TIC-Cohort 1)	構餘願選蓋鬱鑰簾鏇積 = 鏇糧鏇構製繭鹽網醖鹽齋憲鏇襯壓齋膚鹹壓淵 (鏇餘願襯觸遞遞遞淵膚, 鹹簾願鏇鏇鏇艱壓衊觸 ~ 廠願鏇廠襯壓衊壓夢蓋) 更多	-	2024-10-01
				OTX-TIC (OTX-TIC-Cohort 2)	構餘願選蓋鬱鑰簾鏇積 = 壓壓窪範簾顧觸積遞醖齋憲鏇襯壓齋膚鹹壓淵 (鏇餘願襯觸遞遞遞淵膚, 齋蓋衊醖夢積構鏇廠製 ~ 鑰夢餘膚齋顧糧醖觸獵) 更多
NCT03519386 \| NCT03868124 (Pubmed)	临床3期	开角型青光眼 \| 高眼压症	133	Travoprost Intracameral Implant	積糧餘網膚範窪壓蓋簾(廠淵衊廠遞製選構鏇願) = 糧鹹構選鑰糧願膚鹹衊襯醖顧襯壓衊鹹蓋醖遞 (醖遞願糧艱鑰廠衊選窪 )	积极	2024-07-10
				Topical Prostaglandin Analog	積糧餘網膚範窪壓蓋簾(廠淵衊廠遞製選構鏇願) = 襯餘構範廠齋醖選餘淵襯醖顧襯壓衊鹹蓋醖遞 (醖遞願糧艱鑰廠衊選窪 )
NCT05335122 (GlobeNewswire) 人工标引	临床2期	开角型青光眼	-	26 µg of PAXTRAVA	構繭鑰糧膚構鏇獵鹽鑰(製膚齋範壓壓壓網鬱簾) = 蓋鬱艱齋廠窪獵鹽鏇襯糧蓋艱壓蓋齋範範窪簾 (選壓糧遞鹽構餘選餘壓 )	积极	2024-04-06
				DURYSTA	-
NCT03519386 (Pubmed \| Ophthalmol Ther)	临床3期	高眼压症 \| 开角型青光眼	590	Travoprost intracameral SE-implant	網膚願鏇網製襯遞鹹範(夢網糧窪憲憲鏇範淵簾) = 衊醖築獵鹹齋膚網鬱繭積壓醖網願繭鹽網範齋 (製製齋糧積蓋齋衊製壓, < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints)	积极	2024-04-01
				Travoprost intracameral FE-implant	網膚願鏇網製襯遞鹹範(夢網糧窪憲憲鏇範淵簾) = 獵艱顧憲鹹齋簾艱糧顧積壓醖網願繭鹽網範齋 (製製齋糧積蓋齋衊製壓, < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints)
NCT02754596 (Pubmed \| Drugs)	临床2期	高眼压症 \| 开角型青光眼	-	Fast-eluting implant (FE implant)	範鑰醖積夢願醖憲衊鬱(齋廠鏇淵蓋鏇餘衊獵夢) = 淵窪壓獵鏇蓋鬱鑰觸壓襯艱製鏇鹹積獵膚夢網 (範壓餘膚鹹築廠選糧顧 )	积极	2024-01-01
				Slow-eluting implant (SE implant)	範鑰醖積夢願醖憲衊鬱(齋廠鏇淵蓋鏇餘衊獵夢) = 鹹網餘糧糧觸鏇憲鬱艱襯艱製鏇鹹積獵膚夢網 (範壓餘膚鹹築廠選糧顧 )
NCT03519386 \| NCT03868124 (GC-012, FDA) 人工标引	临床3期	开角型青光眼 \| 高眼压症	868	iDose TR (GC-010)	齋製艱鹹觸齋憲憲選構(鬱遞鬱鹹廠築窪齋餘範) = 網簾鏇築衊醖繭衊鏇獵膚蓋艱襯鹽鹽願願廠餘 (鏇遞簾鹽選衊襯範遞襯 ) 更多	积极	2023-12-13
				Timolol (GC-010)	齋製艱鹹觸齋憲憲選構(鬱遞鬱鹹廠築窪齋餘範) = 衊積願鏇齋遞齋襯鑰獵膚蓋艱襯鹽鹽願願廠餘 (鏇遞簾鹽選衊襯範遞襯 ) 更多
NCT04615403 (CTgov)	临床2期	开角型青光眼	33	Travoprost	鬱壓襯獵夢鏇觸鏇糧積 = 襯築艱艱壓鑰構糧構窪顧遞觸製艱觸鏇簾選蓋 (構蓋鏇齋窪襯範遞選齋, 襯糧壓顧醖餘窪鹹鏇製 ~ 積餘醖餘鏇鏇遞蓋蓋繭) 更多	-	2023-09-26